齐帕替尼用于既往接受含铂化疗联合或不联合阿米万单抗治疗的EGFR外显子20插入阳性非小细胞肺癌患者
REZILIENT1是一项I/II期开放标签试验,评估齐帕替尼100 mg每日两次在既往接受含铂化疗联合或不联合ex20ins靶向治疗的EGFR ex20ins突变NSCLC患者中的疗效与安全性。主要疗效人群确认ORR为35.2%(95%CI 28.2-42.8),中位DOR为8.8个月(95%CI 8.3-12.7)。
要点
- 主要疗效人群确认ORR为35.2%,中位DOR为8.8个月。
- 既往未接受ex20ins靶向治疗者ORR为40%,仅接受阿米万单抗者为30%,接受阿米万单抗及其他ex20ins靶向治疗者为14.3%。
- 最常见≥3级治疗相关不良事件为贫血(7%)。
核心结论
- 齐帕替尼在既往接受含铂化疗联合或不联合阿米万单抗的EGFR ex20ins突变NSCLC患者中显示出具有临床意义的疗效,安全性可控。
研究设计与样本
- REZILIENT1(ClinicalTrials.gov标识符:NCT04036682)是一项I/II期开放标签试验,纳入既往接受含铂化疗联合或不联合ex20ins靶向治疗的局部晚期或转移性EGFR ex20ins突变NSCLC患者;允许无症状、已治疗和未治疗的稳定性中枢神经系统转移。
- 报告接受齐帕替尼100 mg每日两次治疗的患者数据;主要终点为独立中心审查评估的客观缓解率(ORR)和缓解持续时间(DOR)。
- 数据截止日期为2024年12月10日,共244例患者接受齐帕替尼100 mg每日两次治疗。
- 主要疗效人群(随访8个月)包括既往接受含铂化疗但未接受ex20ins靶向治疗者(125例)、仅接受阿米万单抗者(30例)、接受阿米万单抗及其他ex20ins靶向治疗者(21例)。
主要发现
- 确认的ORR为35.2%(95%CI 28.2-42.8),中位DOR为8.8个月(95%CI 8.3-12.7)。
- 在既往接受含铂化疗但未接受ex20ins靶向治疗、仅接受阿米万单抗、接受阿米万单抗及其他ex20ins靶向治疗的患者中,确认的ORR分别为40%、30%和14.3%,中位DOR分别为8.8、14.7和4.2个月。
- 在68例中枢神经系统转移患者中,ORR为30.9%。
- 最常见的≥3级治疗相关不良事件为贫血(7%)、肺炎和皮疹(各2.5%)、腹泻、ALT升高和血小板计数降低(各2%)。
关键数值与推荐
- 确认的ORR为35.2%(95%CI 28.2-42.8),中位DOR为8.8个月(95%CI 8.3-12.7)。
- 既往接受含铂化疗但未接受ex20ins靶向治疗者确认ORR为40%,中位DOR为8.8个月。
- 仅接受阿米万单抗者确认ORR为30%,中位DOR为14.7个月。
- 接受阿米万单抗及其他ex20ins靶向治疗者确认ORR为14.3%,中位DOR为4.2个月。
- 68例中枢神经系统转移患者ORR为30.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of zipalertinib, an irreversible epidermal growth factor receptor (EGFR) inhibitor, in pretreated patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations. METHODS: REZILIENT1 (ClinicalTrials.gov identifier: NCT04036682) is a phase I/II open-label trial enrolling patients with locally advanced or metastatic EGFR ex20ins-mutant NSCLC previously treated with platinum-based chemotherapy with/without ex20ins-targeted therapies. Asymptomatic, treated and untreated stable CNS metastases are permitted. We report data from patients treated with zipalertinib 100 mg twice daily. The primary end points are objective response rate (ORR) and duration of response (DOR) by independent central review. RESULTS: At data cutoff (December 10, 2024), 244 patients had received treatment with zipalertinib 100 mg twice daily. The primary efficacy population (8 months' follow-up) comprised patients who had received prior platinum-based chemotherapy without ex20ins-targeted therapy (125 patients), with amivantamab only (30 patients), or with amivantamab and other ex20ins-targeted therapy (21 patients). The confirmed ORR was 35.2% (95% CI, 28.2 to 42.8); median DOR was 8.8 months (95% CI, 8.3 to 12.7). Among patients who received prior platinum-based chemotherapy without ex20ins-targeted therapy, amivantamab only, or amivantamab and other ex20ins-targeted therapy, the confirmed ORR was 40%, 30%, and 14.3%, and median DOR was 8.8, 14.7, and 4.2 months, respectively. Among 68 patients with CNS metastases, the ORR was 30.9%. The most common grade ≥3 treatment-related adverse events were anemia (7%), pneumonitis and rash (2.5% each), and diarrhea, ALT increased, and platelet count decreased (2% each). CONCLUSION: Zipalertinib demonstrated clinically meaningful efficacy with a manageable safety profile in patients with EGFR ex20ins-mutant NSCLC who received prior platinum-based chemotherapy with or without amivantamab.
引用
- Piotrowska Z, Passaro A, Nguyen D, et al. Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. J Clin Oncol. 2025. PMID: 40450572. doi:10.1200/JCO-25-00763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。